Sector News

Ajinomoto Bio-Pharma buys Indian API plant from JV partner

August 30, 2019
Life sciences

Ajinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the CDMO continues to bulk up in a market that favors companies that can do it all.

Ajinomoto Bio-Pharma today announced it is buying the 50% share of the joint venture still owned by Indian partner Granules OmniChem (GOC). The JV was first established in 2011 and operates a plant in Visakhapatnam that manufactures small-molecule intermediates and active pharmaceutical ingredients (APIs). Terms of the deal were not disclosed.

“GOC has been a well-run producer of high-quality API since its formation, which was designed, constructed and is managed based on our Belgian sites’ GMP operating standards and quality systems,” Ajinomoto Bio-Pharma CEO David Enloe said in a statement.

This move follows several others as the company expands and consolidates its operations. In 2018, then Ajinomoto Althea and U.S.-based OmniChem combined their large- and small-molecule operations. Ajinomoto Bio-Pharma Services, which is a wholly owned subsidiary of Tokyo-based Ajinomoto, earlier this year folded GeneDesign into its operations.

The CDMO in 2016 acquired the Japanese CDMO that produces nucleic acid drugs but kept it as a separate company. The operation has a 2,000-square-meter facility in Osaka that manufactures oligonucleotide APIs and does custom synthesis.

The moves by the company mirror some of the steps taken by other CDMOs to expand operations in a variety of areas. Somerset, New Jersey-based Catalent, for one, this year laid out $1.2 billion for Paragon Bioservices to bust into the gene therapy realm. It then followed that up with a $40 million investment at its manufacturing facility in Winchester, Kentucky, to boost its formulation and controlled-release tablet and capsule manufacturing.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend